Artikelen

Arimidex - anastrozole information and study overview

Breast Cancer: Exemestane Exemestane = gives much better effect on overall survival and disease-free and reduced risk of recurrence than tamoxifen so large phase III study. Article updated March 28, 2011

Breast Cancer: Exemestane Exemestane = drug approved by FDA as a treatment for women with breast cancer at the age of the transfer.

Femara: Information on proven effectiveness and use of Femara - Letrozole in breast cancer put together.

Breast cancer: Femara - gives letrozole in women with breast cancer five years tamoxifen who have used a significantly longer disease-free time but not significantly better overall survival compared to placebo.

Hormones: Injections of goserelin - Zoladex given alongside chemotherapy in women with breast cancer who are menstruating completely protect ovaries. Freezing seems better alternative. Article updated August 3, 2011

Hormones: Women who take hormone treatments to counter disadvantages of transition have significantly higher risk of breast cancer and more serious nature of breast cancer, said major long-term study of WHI - Women's Health Initiative

Breast cancer: Hormones in breast cancer: Hormone therapy and during the transition caused 54-93% chance galwegziekte so randomized study of more than 14,000 healthy women.

Hormone therapy: After two to three years to switch from tamoxifen to Arimidex provides significantly less risk of a recurrence of breast cancer, two large randomized trials with a duration of three years.

Hormones: Breast cancer patients who survive hormone treatments / aromaseremmers such as Letrazole - Femara and Arimidex - Anastrazole or survive with the help of chemotherapy experienced still greater risk of osteoporosis = osteoporosis in later life. Tamoxifen causes less osteoporosis later in life than the newer hormone treatments / aromaseremmers which in turn is significantly better effect on the breast itself. Read study abstract explanatory article, osteoporosis and breast cancer in alphabetical list. Article updated August 3, 2011

BRCA1 and BCRA2: Prophylactic mastectomy (preventive surgery of breasts) and salpingo-oophorectomy (removal of ovaries, fallopian tubes plus) in women with BRCA1 and BRCA2 mutation works great at preventing breast cancer and ovarian cancer. Shows a large long-term study of 2500 women and BCRA1 BCRA2 mutation. Article posted September 2, 2010

Red clover isoflavones are not significantly improved bone density on mammography than placebo, significantly better than conventional hormone therapy for women with breast cancer so randomized phase III study. Article updated March 28, 2011

Tamoxifen: Tamoxifen use in breast cancer patients in addition to the antidepressant paroxetine are more likely to die prematurely. This shows a 12 year population in Canada in 2430 women over 66 years with breast cancer. Article posted February 10, 2010

Tamoxifen and radiotherapy: Tackling breast cancer with tamoxifen after surgery and radiation in women over 70 years seems pointless. For women aged 50 years, this approach is sensible for local metastases, although again no difference in getting remote metastasis and survival between the two groups, according to recently published randomized trials. Article updated March 28, 2011.

Tamoxifen: Surgery in older women with breast cancer followed by tamoxifen provides no difference in survival than tamoxifen alone, says five-year randomized study in 476 women. Article updated July 12, 2011

Tamoxifen: Tamoxifen information put together.

Aromasin - Exemestane produces slightly better results in postmenopausal women with breast cancer than Arimidex - Anastrazole but not significantly. Or offers to switch from Arimidex to Aromasin if that fails to catch on more opportunities than the other way. Article posted August 3, 2011

Everolimus (Afinitor) with exemestane provides significantly longer disease-free time for women with hormone sensitive breast cancer, even where there was resistance to Arimidex and Femara. Article posted September 27, 2011

Tamoxifen: Tamoxifen use in breast cancer patients in addition to the antidepressant paroxetine are more likely to die prematurely. This shows a 12 year population in Canada in 2430 women over 66 years with breast cancer. Article posted February 10, 2010

February 10, 2010: Source: BMJ. 2010 Feb 8; 340: c693. doi: 10.1136/bmj.c693

Women with breast cancer who used tamoxifen and also often the antidepressant paroxetine appear to have a significantly increased risk of premature death than tamoxifen alone vroiuwen use. Approx. 1 in 18 women dies earlier paroxetine tamoxifen use in addition to their breast cancer, the researchers said. This shows a 12 year female population in Canada for 66 years and older. The risk of death after 5 years was for women who used paroxetine side tamoxifen 91% while this percentage only tamoxifen users was 75%. This study enrolled 2430 women with breast cancer and tamoxifen use part.

After adjusting for age, duration of tamoxifen treatment, etc., the mortality rate for tamoxifen alone or use. 25%, 50% and 75%. Grope for the regularly used paroxetine were these percentages were respectively: 24%, 54% and 91% increased risk of death from breast cancer (P <0.05 for each comparison). Other antidepressants in addition to tamoxifen were found to have no effect on premature death, the researchers said.

The study was published Monday in the British Medical Journal. Here is the abstract.

BMJ. 2010 Feb 8; 340: c693. doi: 10.1136/bmj.c693.

Selective serotonin reuptake inhibitors and breast cancer mortality in women Receiving Tamoxifen: a population-based cohort study.

CM Kelly , Juurlink DN , Gomes T , Duong-Hua M , Pritchard KI , Austin PC , Paszat LF .

Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada.

OBJECTIVE: To Rise Characterization whether some selective serotonin reuptake inhibitor (SSRI) anti-depressants reducing tamoxifen's effectiveness by inhibiting its bioactivation by cytochrome P450 2D6 (CYP2D6).

DESIGN: Population-based cohort study.

PARTICIPANTS: Women aged 66 years living in Ontario or older Treated with Tamoxifen for Breast Cancer Between 1993 and 2005 who had a single overlapping treatment with SSRIs.

Outcome MAIN MEASURES: Risk of death from breast cancer after tamoxifen treatment completion or, as a function of the Proportion of time on tamoxifen consistently Each SSRI All which was co-Prescribed leg.

RESULTS: Of 2430 Women Treated with Tamoxifen and a single SSRI, 374 (15.4%) died of breast cancer consistently follow up (mean follow up 2.38 years, SD 2.59). After adjustment for age, duration of tamoxifen treatment, and other potential confounders, absolute Increases or 25%, 50%, and 75% in the Proportion of time on tamoxifen with overlapping use of paroxetine (an irreversible inhibitor of CYP2D6) were associated with 24 %, 54%, and 91% Increases in the risk of death from breast cancer, respectively (P <0.05 For Each comparison). By contrast, no such risk was seen with other anti-depressants. That estimate we use or paroxetine for 41% or tamoxifen treatment (the median overlap in our sample) would result in one breast cancer death Additional within-five years or Cessation of tamoxifen for every 7.19 (95% confidence interval 12.5 to 46.3) Patients Treated SO , the risk with more overlap would be Greater extensification.

CONCLUSION: Paroxetine use was consistently associated with tamoxifen treatment an Increased Risk of death from breast cancer, supporting the hypothesis can paroxetine That Abolish or reducing the benefit of tamoxifen in women with breast cancer.

PMID: 20142325 [PubMed - in process]